Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • CNP520: Phase II started

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: CNP520 Business: Neurology Molecular target: NA Description: Betasite APP-cleaving enzyme (BACE) inhibitor …

    Published on 9/12/2016
  • DENVax: Phase III started

    Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Product: DENVax (Dengue fever vaccine) (TAK-003) Business: Infectious Molecular target: NA Description: Recombinant tetravalent attenuated live dengue vaccine …

    Published on 9/12/2016
  • GMI-1359: Phase I started

    GlycoMimetics Inc. (NASDAQ:GLYC), Rockville, Md. Product: GMI-1359 Business: Cancer Molecular target: E selectin (SELE) (CD62E); CXC chemokine receptor 4 (CXCR4) (NPY3R) Description: Dual antagonist of E selectin (SELE;…

    Published on 9/12/2016
  • IV BAL101553: Phase I/IIa started

    Basilea Pharmaceutica AG (SIX:BSLN), Basel, Switzerland Product: IV BAL101553 Business: Cancer Molecular target: Tubulin Description: Water-soluble prodrug of BAL27862, an apoptosis-inducing small molecule targeting …

    Published on 9/12/2016
  • LentiGlobin BB305 gene therapy: Phase III started

    bluebird bio Inc. (NASDAQ:BLUE), Cambridge, Mass. Product: LentiGlobin BB305 gene therapy Business: Hematology Molecular target: NA Description: Autologous CD34+ stem cells transduced ex vivo with a lentiviral vector …

    Published on 9/12/2016
  • Lorediplon: Completed Phase IIa enrollment

    Ergomed plc (LSE:ERGO), Guilford, U.K. Grupo Ferrer Internacional S.A., Barcelona, Spain Ildong Pharmaceutical Co. Ltd. (KSE:000230), Seoul, South Korea Product: Lorediplon Business: Neurology Molecular target: GABA A …

    Published on 9/12/2016
  • MOR00208: Phase II/III started

    MorphoSys AG (Xetra:MOR), Martinsried, Germany Xencor Inc. (NASDAQ:XNCR), Monrovia, Calif. Product: MOR00208, MOR208 (formerly XmAb5574) Business: Cancer Molecular target: CD19 Description: Fc-optimized human mAb …

    Published on 9/12/2016
  • NPT088: Phase Ib started

    Proclara Biosciences Inc., Cambridge, Mass. Product: NPT088 Business: Neurology Molecular target: Beta amyloid; Microtubule-associated protein tau (tau) (MAPT) (FTDP-17) Description: Fusion protein combining Proclaras …

    Published on 9/12/2016
  • Ronopterin: Phase III started

    vasopharm GmbH, Wuerzburg, Germany Product: Ronopterin (VAS203) Business: Inflammation Molecular target: Nitric oxide (NO) synthase Description: Allosteric nitric oxide (NO) synthase inhibitor Indication: Treat …

    Published on 9/12/2016
  • Viaskin rPT: Phase I started

    BioNet-Asia Co. Ltd., Bangkok, Thailand DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT), Bagneux, France University of Geneva, Geneva, Switzerland Product: Viaskin rPT Business: Infectious Molecular target: NA …

    Published on 9/12/2016
  • Yeliva: Phase Ib/II started

    Apogee Biotechnology Corp., Hummelstown, Pa. RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL), Tel Aviv, Israel Product: Yeliva (ABC294640) Business: Cancer Molecular target: Sphingosine kinase 2 (SPHK2) Description:…

    Published on 9/12/2016
  • ZYN002: Phase II started

    Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE), Radnor, Pa. Product: ZYN002 Business: Autoimmune Molecular target: NA Description: Synthetic cannabidiol (CBD) formulated as a transdermal gel Indication: Treat osteoarthritis…

    Published on 9/12/2016
  • AST-OPC1: Phase I/IIa ongoing

    Asterias Biotherapeutics Inc. (NYSE-M:AST), Menlo Park, Calif. Product: AST-OPC1 Business: Neurology Molecular target: NA Description: Human embryonic stem cell (hESC)-derived oligodendrocyte progenitor cells Indication…

    Published on 9/5/2016
  • BPX-01: Phase IIb started

    BioPharmX Corp. (NYSE-M:BPMX), Menlo Park, Calif. Product: BPX-01 Business: Dermatology Molecular target: NA Description: Topical formulation of minocycline, a semisynthetic derivative of tetracycline Indication: Treat …

    Published on 9/5/2016
  • CERC-501: Phase II started

    Cerecor Inc. (NASDAQ:CERC), Baltimore, Md. Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: CERC-501 (formerly LY2456302) Business: Neurology Molecular target: Kappa opioid receptor (KOR) (OPRK1) Description: …

    Published on 9/5/2016
  • CMV eVLP: Phase I ongoing

    VBI Vaccines Inc. (NASDAQ:VBIV; TSX:VBV), Cambridge, Mass. Product: CMV eVLP (VBI-1501A) Business: Infectious Molecular target: NA Description: Vaccine based on VBIs enveloped virus-like particle (eVLP) platform …

    Published on 9/5/2016
  • Demcizumab: Completed Phase II enrollment

    OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), Redwood City, Calif. Product: Demcizumab (OMP-21M18) Business: Cancer Molecular target: Delta-like 4 (DLL4) Description: Humanized IgG2 mAb against delta-like 4 (DLL4) …

    Published on 9/5/2016
  • DRX-065: Phase Ia started

    DeuteRx LLC, Andover, Mass. Product: DRX-065 Business: Hepatic, Neurology Molecular target: Peroxisome proliferation activated receptor (PPAR) gamma Description: Deuterated R-enantiomer of pioglitazone, a …

    Published on 9/5/2016
  • Durasert screw implant: Phase I/II started

    pSivida Corp. (NASDAQ:PSDV; ASX:PVA), Watertown, Mass. Hospital for Special Surgery, New York, N.Y. Product: Durasert screw implant Business: Autoimmune Molecular target: NA Description: Screw implant delivering …

    Published on 9/5/2016
  • Durvalumab: Phase I started

    AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Durvalumab (MEDI4736) Business: Cancer Molecular target: Programmed cell death 1 ligand 1 (PD-L1) (B7-H1) (CD274) Description: Human IgG1 mAb targeting PD-L1 …

    Published on 9/5/2016
  • Edoxaban: Phase III started

    Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan Product: Edoxaban (Savaysa, Lixiana) (DU-176b) Business: Cardiovascular Molecular target: Factor Xa Description: Oral Factor Xa inhibitor Indication: Prevent stroke and…

    Published on 9/5/2016
  • Eryaspase: Completed Phase IIb enrollment

    Erytech Pharma S.A. (Euronext:ERYP), Lyon, France Product: Eryaspase (Graspa, ERY-ASP) (ERY001) Business: Cancer Molecular target: NA Description: L-asparaginase encapsulated in red blood cells Indication: Treat acute …

    Published on 9/5/2016
  • Filgotinib: Phase III started

    Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG), Mechelen, Belgium Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Product: Filgotinib (GS-6034, GLPG0634) Business: Autoimmune Molecular target: Janus kinase-1 (JAK-1…

    Published on 9/5/2016
  • Galeterone: Phase II discontinued

    Tokai Pharmaceuticals Inc. (NASDAQ:TKAI), Cambridge, Mass. Product: Galeterone (TOK-001) Business: Cancer Molecular target: Androgen receptor; Cytochrome P450 17 alpha-hydroxylase/C17, 20 lyase (CYP17) (CYP17A) …

    Published on 9/5/2016
  • HLD100: Phase II started

    Highland Therapeutics Inc., Toronto, Ontario Product: HLD100 Business: Neurology Molecular target: NA Description: Delayed- and extended-release formulation of dextroamphetamine sulfate Indication: Treat ADHD Endpoint: …

    Published on 9/5/2016

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993